Clinical presentation of anaplastic large-cell lymphoma in the central nervous system

Masashi Nomura, Yoshitaka Narita, Yasuji Miyakita, Makoto Ohno, Shintaro Fukushima, Takashi Maruyama, Yoshihiro Muragaki, Soichiro ShibuiMolecular 2013 · DOI

TL;DR

This paper investigates Anaplastic Large-Cell Lymphoma (ALCL) in the central nervous system (CNS), a rare T-cell lymphoma. It finds that ALK-positive ALCL, occurring in younger patients, has a significantly better prognosis and responds well to chemotherapy, particularly methotrexate-based regimens.

What Problem Does This Paper Address?

Primary Central Nervous System Lymphoma (PCNSL) is predominantly composed of diffuse large B-cell lymphomas (DLBCLs). Anaplastic Large-Cell Lymphoma (ALCL), a type of T-cell lymphoma, is a rare subtype of PCNSL. Due to its rarity, the clinical presentation, prognostic factors, and optimal treatment strategies for CNS ALCL have not been well-established. This study aims to clarify these aspects by reviewing existing literature and presenting a case study.

Methods

The researchers conducted a literature search on PubMed for immunocompetent patients with ALCL of the brain, using keywords like "anaplastic large-cell lymphoma," "ALK," and "primary central nervous system lymphoma." They collected data on age, gender, location, ALK status, treatment, and clinical course from 26 previously reported cases and included one case treated at their institution, totaling 27 patients. Overall survival (OS) was analyzed using the Kaplan-Meier survival method, with statistical analysis performed using JMP software. They also presented a detailed case study of a patient with ALK-positive ALCL.

Datasets

The study utilized a dataset compiled from previously published case reports and one case from their own institution. This dataset comprised 27 patients with ALCL of the CNS. No new datasets or benchmarks were introduced.

Key Insights and Ideas

  • ALK Status is a Major Prognostic Factor: The presence or absence of Anaplastic Lymphoma Kinase (ALK) is a critical determinant of prognosis in CNS ALCL.
  • Age Matters: Younger patients (especially those under 40) with ALK-positive ALCL fare significantly better than older patients.
  • Chemotherapy is Key: Chemotherapy, particularly methotrexate-based regimens, appears to be a crucial component of successful treatment for CNS ALCL.
  • ALK-Positive ALCL is More Favorable: ALK-positive ALCL, often seen in younger individuals, has a much better survival rate compared to its ALK-negative counterpart.
  • ALK-Negative ALCL is Aggressive: ALK-negative ALCL presents a more challenging clinical picture with a significantly poorer prognosis, often leading to fatal outcomes.

Key Results

  • Patient Demographics: The study included 27 patients (19 male, 8 female) with a median age of 20 years.
  • ALK Status Distribution: 13 patients (48.1%) were ALK-positive, 9 (33.3%) were ALK-negative, and ALK status was undetermined in 5 (18.5%).
  • Age and ALK Correlation: ALK-positive ALCL occurred in younger patients (median age 17 years), while ALK-negative ALCL was predominantly seen in older patients (median age 65 years).
  • Survival Outcomes:
    • ALK-positive ALCL had a favorable course with a 5-year OS of 75.0%.
  • ALK-negative ALCL presented with a poor prognosis and fatal outcomes (5-year OS <12.5%).
  • Patients younger than 40 years had a significantly longer OS compared to those older than 40.
  • Treatment Efficacy: Chemotherapy improved patient survival. Chemoradiotherapy showed a trend towards improved OS compared to radiotherapy alone.
  • Case Study Success: A 20-year-old patient with ALK-positive ALCL achieved a complete remission with high-dose methotrexate (HD-MTX) alone and remained recurrence-free for over 5 years.

Limitations and Future Work

  • Limited Data: The study acknowledges that its review was based on incomplete data from the literature due to the rarity of CNS ALCL.
  • Need for Larger Studies: The authors emphasize the need for additional multicenter studies with larger patient cohorts to further solidify findings and establish definitive treatment guidelines.
  • Standard Treatment Uncertainty: While MTX-based chemotherapy is recommended, the paper notes that CHOP regimens have not been proven effective for CNS ALCL, and the possibility of chemotherapy alone for ALK-positive ALCL is still under consideration.
  • Potential for Misdiagnosis: The paper highlights that primary ALCL in the CNS can mimic infectious or immunological diseases, underscoring the importance of early diagnosis and timely treatment.

Summary updated

Abstract

The majority of primary central nervous system (CNS) lymphomas are diffuse large B-cell lymphomas (DLBCLs) and anaplastic large-cell lymphoma (ALCL) is a type of T-cell tumor that is rare in the CNS. The aim of this study was to elucidate the clinical presentation and standard therapy of ALCLs by investigating reported cases. Additionally, a case of anaplastic lymphoma kinase (ALK)-positive ALCL in a 20-year-old man who exhibited no recurrence for >5 years following high-dose methotrexate (HD-MTX) treatment was described. Twenty-six immunocompetent patients with ALCL of the CNS that were previously reported and 1 case of ALCL of the CNS treated at our hospital were investigated. Overall survival (OS) was analyzed in relation to survival factors such as age, ALK status and the treatment regimen. The male:female ratio of the patients was 19:8. Of the 27 patients, 13 (48.1%) were ALK-positive, 9 (33.3%) were ALK-negative and the ALK status was not determined in the remaining 5 patients (18.5%). ALK-positive ALCL occurred at a younger age (median age, 17 years) and exhibited a favorable course (5-year OS, 75.0%), whereas ALK-negative ALCL presented at an older age (median age, 65 years) and resulted in fatal outcomes (5-year OS, <12.5%). Similar to the findings for systemic ALCL, ALK positivity, age <40 years and chemotherapy are associated with long-term survival for ALCL of the CNS. Chemoradiotherapy including methotrexate is recommended for ALCL and the possibility of treatment with chemotherapy alone for ALK-positive ALCL is currently under consideration.
BibTeX
@inproceedings{nomura2013clinical,
  author = {Masashi Nomura and Yoshitaka Narita and Yasuji Miyakita and Makoto Ohno and Shintaro Fukushima and Takashi Maruyama and Yoshihiro Muragaki and Soichiro Shibui},
  title = {{Clinical presentation of anaplastic large-cell lymphoma in the central nervous system}},
  booktitle = {Molecular},
  year = {2013},
  doi = {10.3892/mco.2013.110},
}
Figure